Life Sciences Insights | McKinsey & Company
...Read our latest research, articles, and reports on Life Sciences on the changes that matter most for the challenges and opportunities ahead....
https://www.mckinsey.com/industries/life-sciences/our-insights
Key trends shaping biopharma dealmaking in 2025 | McKinsey & Company
...Biopharma dealmaking is critical to innovation in the life sciences sector. We look at some of the key trends shaping the industry in 2025 and beyond....
https://www.mckinsey.com/industries/life-sciences/our-insights/the-synthesis/pulse-check-key-trends-shaping-biopharma-dealmaking-in-2025
Engaging successfully with life sciences investors | McKinsey
...Value creation in life sciences tends to come in waves. The life sciences sector?including pharma, biotech, and medtech?has historically delivered solid long-term returns and has recently corrected from its COVID-19-era spike (Exhibit 1)....
https://www.mckinsey.com.br/industries/life-sciences/our-insights/clear-credible-compelling-mastering-investor-engagement-in-life-sciences
LIFE SCIENCES INDUSTRY REPORT 2025 - pharmaphorum.com
...Uncover the transformative trends that will drive the life sciences industry ahead, backed by expert commentary and data-driven insights....
https://pharmaphorum.com/sites/default/files/2025-01/Life-Sciences-Industry-Report-2025-pt3.pdf
Outlook on pharma operations - McKinsey & Company
...Freeing up $25 billion in cash from inventory On average, pharma underperforms on working capital management. The average pharmaco holds 180 days of finished goods inventory on hand, for example, with top performers at about 100 days. Their peers in the consumer goods industry hold only 60 days? inventory, based on McKinsey benchmarks....
https://www.mckinsey.de/~/media/McKinsey/Business%20Functions/Operations/Our%20Insights/Outlook%20on%20pharma%20operations/Outlook_on_pharma_operations.pdf
Transforming Healthcare and Life Sciences: Key Insights from McKinsey
...On May 31, 2025, a McKinsey survey revealed that 85% of leaders in healthcare?from payers to technology groups?are currently exploring or using generative AI technologies. In the life sciences sector, generative AI could potentially unlock between $60 billion to $110 billion in value....
https://biotechknowledgist.com/transforming-healthcare-and-life-sciences-key-insights-from-mckinsey/
Justice Department Announces Resolution of Criminal and Civil ...
...McKinsey & Company Inc. (McKinsey), a global management consulting firm based in New York, has agreed to pay $650 million to resolve a criminal and civil investigation into the firm?s......
https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/doj-press-releases-involving-fda-oci/justice-department-announces-resolution-criminal-and-civil-investigations-mckinsey-companys-work
Speed up biopharma clinical trials to boost R&D output | McKinsey
...Biopharma sponsors are seeking to accelerate clinical trials and reduce costs through a set of targeted actions aimed at improving patient and site engagement and enrollment productivity....
https://www.mckinsey.com.br/industries/life-sciences/our-insights/accelerating-clinical-trials-to-improve-biopharma-r-and-d-productivity
Transformations for life sciences companies | McKinsey
...Efforts by life sciences companies to drive a step-change in their performance have yielded mixed results. Adhering to five principles can greatly improve the odds of a transformation program succeeding....
https://www.mckinsey.de/industries/life-sciences/our-insights/against-the-odds-how-life-sciences-companies-excel-in-large-transformations
Life Sciences Practice The emerging epicenter: Asia?s role in biopharma ...
...The emerging epicenter: Asia?s role in biopharma?s future is published by McKinsey?s Life Sciences Practice. McKinsey & Company 1200 19th Street NW Fl. 10-11, Suite 1100 Washington, DC 20036 Authors: Anirudh Roy Popli, Fangning Zhang, Jay Park, and Franck De Leu Editors: Gwyn Herbein, Imprint Art director: Aphra Communications: Aeri Yeo...
https://repository.ach.gov.ru/upload/cards/c78/the-emerging-epicenter-asias-role-in-biopharmas-future%20(1).pdf